Get in touch with us
Scientist preparing laboratory samples at sterile workstation

Advance Your Clinical Program with Bioanalytical Solutions

Deliver reliable pharmacokinetic, pharmacodynamic, and immunogenicity data through scientifically driven bioanalytical testing aligned to your clinical objectives.

Generate reliable bioanalytical data across clinical development

Generating meaningful bioanalytical data requires more than assay performance alone. It depends on robust analytical methods, validated workflows, and scientific expertise aligned to study objectives and clinical endpoints.

From early development through clinical trials, we partner with you to design bioanalytical strategies tailored to your program. Our teams bring expertise across complex biologic modalities, including monoclonal antibodies, antibody-drug conjugates, vaccines, and cell and gene therapies.

Through validated workflows and globally harmonized quality standards, we help you generate data that stands up to regulatory scrutiny at every stage of development.

Frame 919 (5)

Why choose Cerba Research for your bioanalytical strategy?

Supporting your bioanalytical strategy across clinical development

We support bioanalytical testing across all phases of development, combining method development, validation, and sample analysis to deliver reliable and reproducible results aligned to your clinical objectives.

Pharmacokinetic (PK) analysis

Pharmacodynamic (PD) and biomarker analysis

Immunogenicity assessment

Bioanalytical method development and validation

Pharmacokinetic (PK) analysis

Understanding drug exposure is essential for evaluating safety, efficacy, and dose selection. To support this, we generate quantitative PK data across a range of therapeutic modalities, enabling informed clinical decision-making and regulatory submissions.

Capabilities include:

  • Small molecule and biologics PK assays
  • Ligand-binding assay platforms
  • Sample analysis across clinical phases
  • PK data generation and reporting
Frame 919

Pharmacodynamic (PD) and biomarker analysis

Linking drug exposure to biological response provides critical insight into mechanism of action and treatment effect. We apply this through PD and biomarker assays designed to evaluate target engagement and clinical response.

Capabilities include:

  • PD biomarker assay development and testing
  • Target engagement and pathway analysis
  • Integration with broader biomarker strategies
  • Data aligned to clinical endpoints
M2 Headers (1)

Immunogenicity assessment

Monitoring immune response to biologics is essential for understanding both safety and efficacy. To support your program, we develop and implement immunogenicity strategies to detect and characterize anti-drug antibodies and their clinical impact.

Capabilities include:

  • Anti-drug antibody (ADA) screening and confirmatory assays
  • Neutralizing antibody (NAb) assessments
  • Tiered immunogenicity testing strategies
  • Regulatory-aligned assay approaches
Medium shot of two scientists smiling and collaborating at laboratory bench

Bioanalytical method development and validation

Robust analytical methods are essential for generating reliable and reproducible data. We develop, optimize, and validate these methods to ensure performance is aligned to intended use and study requirements.

Capabilities include:

  • Method development and optimization
  • Fit-for-purpose validation
  • Sensitivity and performance characterization
  • Validation documentation and reporting
Medium shot of two scientists reviewing laboratory documentation together

Supporting services for your bioanalytical strategy

Frame 1000 (1)

Biomarkers

Design biomarker strategies that help you answer critical clinical and biological questions.

Frame 1000 (2)

Assay development and technology transfer

Develop robust assays and transfer methods that align with your study objectives and requirements.

Frame 1000

Genomics

Translate genomic complexity into meaningful evidence that supports your clinical development decisions.

Scientist inspecting biological sample tube in laboratory

Flow cytometry

Characterize cellular responses with flow cytometry strategies tailored to your clinical objectives.

shutterstock_1255890574-1-scaled.jpg

Histopathology

Understand disease biology through integrated pathology approaches and biomarker evaluation.

Scientists reviewing laboratory notes and results together

Protocol development

Align your analytical strategy with study design, endpoints, and regulatory expectations.

Let’s design your bioanalytical strategy

Whether you’re evaluating pharmacokinetics, assessing immunogenicity, or integrating biomarker data, we work with you to deliver reliable, decision-ready results.

Bioanalysis resources and insights

Whitepaper

Bioanalytical Solutions for Biologics and Complex Therapies

Explore bioanalytical approaches supporting pharmacokinetics and immunogenicity assessment across biologics, including method development, validation, and sample analysis.

Overcoming-Bioanalytical-Challenges-in-Anti-Drug-Antibody-Detection-for-Antibody-Drug-Conjugates_Sun_Dark
Webinar

Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs

Learn how tailored immunogenicity strategies support the detection and characterization of anti-drug antibodies in complex biologics such as antibody-drug conjugates.

Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for ADCs (1)

Bioanalysis FAQ